This trial is testing a combination of drugs to see if it can make previously inoperable tumors resectable in patients with kidney cancer.
1 Primary · 3 Secondary · Reporting Duration: Screening (within 14 days of Day 1) and pre-surgery (week 9-10). 1) If metastatic disease followup monthly or 2) if no evidence of disease followup every three months until five years or death.
Experimental Treatment
15 Total Participants · 1 Treatment Group
Primary Treatment: Lenvatinib · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: